These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 38921460)

  • 1. Crosstalk between Epigenetics and Metabolic Reprogramming in Metabolic Dysfunction-Associated Steatotic Liver Disease-Induced Hepatocellular Carcinoma: A New Sight.
    Li A; Wang R; Zhao Y; Zhao P; Yang J
    Metabolites; 2024 Jun; 14(6):. PubMed ID: 38921460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma.
    Wang Y; Fleishman JS; Li T; Li Y; Ren Z; Chen J; Ding M
    Front Pharmacol; 2023; 14():1336216. PubMed ID: 38313077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AKR1B1 drives hyperglycemia-induced metabolic reprogramming in MASLD-associated hepatocellular carcinoma.
    Syamprasad NP; Jain S; Rajdev B; Panda SR; Kumar GJ; Shaik KM; Shantanu PA; Challa VS; Jorvekar SB; Borkar RM; Vaidya JR; Tripathi DM; Naidu VGM
    JHEP Rep; 2024 Feb; 6(2):100974. PubMed ID: 38283757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenotypes of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatocellular Carcinoma.
    Rivera-Esteban J; Muñoz-Martínez S; Higuera M; Sena E; Bermúdez-Ramos M; Bañares J; Martínez-Gomez M; Cusidó MS; Jiménez-Masip A; Francque SM; Tacke F; Minguez B; Pericàs JM
    Clin Gastroenterol Hepatol; 2024 Sep; 22(9):1774-1789.e8. PubMed ID: 38604295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic regulation of hepatocellular carcinoma in non-alcoholic fatty liver disease.
    Tian Y; Wong VW; Chan HL; Cheng AS
    Semin Cancer Biol; 2013 Dec; 23(6 Pt B):471-82. PubMed ID: 24018165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interplay between gut microbiome, host genetic and epigenetic modifications in MASLD and MASLD-related hepatocellular carcinoma.
    Ha S; Wong VW; Zhang X; Yu J
    Gut; 2024 Dec; 74(1):141-152. PubMed ID: 38950910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histidine-rich glycoprotein in metabolic dysfunction-associated steatohepatitis-related disease progression and liver carcinogenesis.
    Foglia B; Sutti S; Cannito S; Rosso C; Maggiora M; Casalino A; Bocca C; Novo E; Protopapa F; Ramavath NN; Provera A; Gambella A; Bugianesi E; Tacke F; Albano E; Parola M
    Front Immunol; 2024; 15():1342404. PubMed ID: 38469298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crosstalk between metabolic reprogramming and epigenetics in cancer: updates on mechanisms and therapeutic opportunities.
    Ge T; Gu X; Jia R; Ge S; Chai P; Zhuang A; Fan X
    Cancer Commun (Lond); 2022 Nov; 42(11):1049-1082. PubMed ID: 36266736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unraveling the Sweet Secrets of HCC: Glucometabolic Rewiring in Hepatocellular Carcinoma.
    Bhat SA; Farooq Z; Ismail H; Corona-Avila I; Khan MW
    Technol Cancer Res Treat; 2023; 22():15330338231219434. PubMed ID: 38083797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Familial coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: Nationwide multigenerational cohort study.
    Ebrahimi F; Hagström H; Sun J; Bergman D; Shang Y; Yang W; Roelstraete B; Ludvigsson JF
    J Hepatol; 2023 Dec; 79(6):1374-1384. PubMed ID: 37647992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modifiable Risk Factors for Hepatocellular Carcinoma in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-Analysis.
    Xiao S; Liu Y; Fu X; Chen T; Xie W
    Am J Med; 2024 Nov; 137(11):1072-1081.e32. PubMed ID: 39047929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MASLD-Related HCC: A Comprehensive Review of the Trends, Pathophysiology, Tumor Microenvironment, Surveillance, and Treatment Options.
    Shi Y; Taherifard E; Saeed A; Saeed A
    Curr Issues Mol Biol; 2024 Jun; 46(6):5965-5983. PubMed ID: 38921027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lower hepatocellular carcinoma surveillance in metabolic dysfunction-associated steatotic liver disease: Impact on treatment eligibility.
    Henry-Blake C; Balachandrakumar V; Kassab M; Devonport J; Matthews C; Fox J; Baggus E; Henney A; Stern N; Cuthbertson DJ; Palmer D; Johnson PJ; Hughes DM; Hydes TJ; Cross TJS
    J Gastroenterol Hepatol; 2024 Aug; ():. PubMed ID: 39191435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of MASLD-related hepatocellular carcinoma: progress in pathogenesis, early detection, and therapeutic interventions.
    Ma Y; Wang J; Xiao W; Fan X
    Front Med (Lausanne); 2024; 11():1410668. PubMed ID: 38895182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic dysfunction-associated steatotic liver disease has become the most common cause of hepatocellular carcinoma in Sweden: A nationwide cohort study.
    Vaz J; Jepsen P; Strömberg U; Midlöv P; Eriksson B; Buchebner D; Hagström H
    Int J Cancer; 2025 Jan; 156(1):40-51. PubMed ID: 39016032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MASLD and the Development of HCC: Pathogenesis and Therapeutic Challenges.
    Phoolchund AGS; Khakoo SI
    Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic dysfunction-associated steatotic liver disease increases hepatocellular carcinoma risk in chronic hepatitis B patients: a retrospective cohort study.
    Lin M; Gao B; Peng M; Chen X; Xiao H; Shi M; Zhang X; Zeng F; Chi X
    Front Physiol; 2024; 15():1347459. PubMed ID: 38405121
    [No Abstract]   [Full Text] [Related]  

  • 18. Rifaximin on epigenetics and autophagy in animal model of hepatocellular carcinoma secondary to metabolic-dysfunction associated steatotic liver disease.
    Michalczuk MT; Longo L; Keingeski MB; Basso BS; Guerreiro GTS; Ferrari JT; Vargas JE; Oliveira CP; Uribe-Cruz C; Cerski CTS; Filippi-Chiela E; Álvares-da-Silva MR
    World J Hepatol; 2024 Jan; 16(1):75-90. PubMed ID: 38313241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Τ cell-mediated adaptive immunity in the transition from metabolic dysfunction-associated steatohepatitis to hepatocellular carcinoma.
    Papadopoulos G; Giannousi E; Avdi AP; Velliou RI; Nikolakopoulou P; Chatzigeorgiou A
    Front Cell Dev Biol; 2024; 12():1343806. PubMed ID: 38774646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ncRNA-mediated fatty acid metabolism reprogramming in HCC.
    Xu K; Xia P; Chen X; Ma W; Yuan Y
    Trends Endocrinol Metab; 2023 May; 34(5):278-291. PubMed ID: 36890041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.